GLP-1 drugs for addiction: who is running trials in 2026 and what to expect

TL;DR

As of early 2026, at least 10 clinical trials are actively running or recently completed across the US, UK, and Europe testing GLP-1 medications for alcohol use disorder, opioid use disorder, nicotine dependence, and stimulant use disorders. Sponsored by the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and several universities, the trials use semaglutide, liraglutide, and exenatide. Results are expected throughout 2026-2028 and could reshape addiction pharmacotherapy.

GLP-1 users started reporting it informally first: "I just stopped wanting to drink." "I've barely smoked since starting Ozempic." "I don't even think about opioids the same way." These reports were anecdotal but pervasive enough that the addiction research community took notice. Now the science is catching up to the patient reports. GLP-1 medications appear to dampen cravings not just for food but for substances of abuse - and the clinical trial machine has kicked into gear to prove it rigorously.

Why GLP-1 medications might reduce addiction

The biology behind GLP-1 and addiction centres on the mesolimbic dopamine reward system - the same neural circuitry that drives both eating behaviour and substance dependence. GLP-1 receptors are expressed in the ventral tegmental area (VTA), the nucleus accumbens, and the prefrontal cortex - the core circuit for reward, motivation, and craving.

When alcohol, opioids, nicotine, or stimulants are consumed, they trigger dopamine release in the nucleus accumbens - producing the rewarding effect that reinforces continued use. GLP-1 receptor activation in the mesolimbic system appears to modulate this dopamine signal, dampening the reward response to addictive substances. The result, in animal models and human reports, is a reduction in the motivational salience of the substance - things that once felt compulsively desirable become easier to resist or simply less interesting.

This is a fundamentally different mechanism from existing addiction pharmacotherapies like naltrexone (which blocks opioid receptors) or bupropion (which affects dopamine and noradrenaline reuptake). GLP-1's mechanism is upstream in the reward circuitry, modulating the dopamine signal at its source rather than blocking receptor binding downstream.

The active trial landscape in 2026

Alcohol use disorder

Alcohol use disorder has the most active GLP-1 trial pipeline. Key trials include:

• NIAAA-sponsored semaglutide trial at the University of North Carolina - testing 0.5 mg and 1 mg weekly semaglutide vs placebo in alcohol use disorder over 16 weeks. Primary outcomes: drinks per week, days of heavy drinking, alcohol cravings. Expected results: 2026.
• Semaglutide in alcohol use disorder - King's College London and University College London collaborative trial testing semaglutide's effects on alcohol consumption and cue reactivity (brain imaging showing response to alcohol-related cues). This trial includes neuroimaging to directly measure reward circuitry changes.
• The Aarhus University trial in Denmark testing liraglutide vs placebo in alcohol use disorder, examining both consumption and biomarkers of liver damage. Denmark has among the highest GLP-1 prescribing rates globally and leads European addiction research in this space.

A 2025 JAMA Psychiatry study provided early Phase 2 evidence: 0.5 mg semaglutide reduced total alcohol cravings vs placebo at nine weeks (p=0.0219) and decreased drinks per drinking day. This was not a treatment trial per se but established that the craving signal is real and measurable.

Opioid use disorder

NIDA (National Institute on Drug Abuse) is funding at least two semaglutide trials in opioid use disorder. The interest is particularly strong given the scale of the opioid crisis: over 80,000 opioid-related deaths per year in the US, with existing pharmacotherapies (methadone, buprenorphine, naltrexone) showing significant adherence problems. Early signals from large database studies are encouraging: a VA study of 600,000 veterans found GLP-1 users had a 14% lower risk of developing any new substance use disorder compared to matched controls.

The opioid trials face a methodological challenge: many opioid use disorder patients are on buprenorphine or methadone maintenance, and GLP-1 interactions with opioid receptor blockade need to be carefully managed. Trials are running in both opioid-naive and opioid-maintained populations.

Nicotine and tobacco use

Multiple small trials are testing GLP-1 medications for smoking cessation. One published Danish study found GLP-1 users had significantly higher smoking cessation rates than matched controls. A University of Pennsylvania trial is testing exenatide as an adjunct to standard nicotine replacement therapy. The nicotine indication is considered among the most scientifically plausible given the strong role of dopamine reward in nicotine dependence and the clear human self-reports of reduced smoking desire on GLP-1 medications.

Stimulant use disorders (cocaine, methamphetamine)

Cocaine and methamphetamine use disorder have essentially no approved pharmacotherapies in the US. The possibility that GLP-1 medications could reduce stimulant cravings is one of the most consequential questions in the entire addiction medicine field. NIDA-funded investigators are running pilot trials with semaglutide in cocaine-using adults. Animal model data is strong - rodents on GLP-1 medications show dramatically reduced cocaine self-administration. Human trial results are expected beginning in 2027.

What the VA data adds to the picture

One of the most robust pieces of evidence comes not from a trial but from a real-world analysis of 600,000+ US veterans. GLP-1 users in this population showed:

• 14% lower overall risk of developing new substance use disorder
• Significant reductions specifically in alcohol use disorder incidence
• Reduced nicotine dependence diagnoses
• Lower rates of cannabis and stimulant use disorders

This is a dataset orders of magnitude larger than any clinical trial currently running. While it cannot establish causality (VA patients on GLP-1s may differ systematically from those not on them), the consistency and breadth of the signal across multiple substance types is compelling.

What this means for GLP-1 users right now

No GLP-1 medication is currently approved for any addiction indication. If you notice spontaneous reductions in cravings for alcohol, nicotine, or other substances after starting GLP-1 therapy, this is consistent with the emerging pharmacological evidence - but these effects are not guaranteed, are not universally experienced, and are not a substitute for evidence-based addiction treatment.

What does matter now, regardless of addiction outcomes: GLP-1 medications create documented nutrient gaps through appetite suppression. Alcohol independently depletes B12, folate, magnesium, and zinc - nutrients already at risk in GLP-1 users. If you are using GLP-1 medications while drinking alcohol, the compounded nutritional risk is real and worth addressing proactively. GLP-1 Shield is specifically designed for the nutrient depletion risks of GLP-1 therapy.

Frequently asked questions

Are GLP-1 medications approved to treat addiction?

No. As of June 2026, no GLP-1 medication (semaglutide, tirzepatide, liraglutide, orforglipron, or others) is approved for any addiction or substance use disorder indication. Multiple clinical trials are running, and early signals are promising, but FDA approval for addiction indications - if it happens - is likely 2028 at the earliest given standard Phase 3 timelines.

Does Ozempic reduce alcohol cravings?

Based on a 2025 JAMA Psychiatry Phase 2 trial and multiple patient reports, semaglutide appears to reduce alcohol cravings in some people - with statistically significant differences seen in cravings and drinks per drinking day at nine weeks. The mechanism is GLP-1 receptor modulation of the mesolimbic dopamine reward system. However, not everyone experiences this effect, and it is not an approved use of the medication.

Which GLP-1 trials for addiction are most advanced in 2026?

Alcohol use disorder trials are the most advanced, with NIAAA-funded semaglutide trials at the University of North Carolina and collaborative UK trials expected to report in 2026. NIDA-funded opioid use disorder semaglutide trials and nicotine cessation exenatide trials are in earlier phases. Stimulant use disorder (cocaine, methamphetamine) trials are in pilot stages with results expected 2027-2028.

Why would a drug for diabetes help with addiction?

GLP-1 receptors are not only in the pancreas and gut - they are expressed throughout the brain, including in the reward circuitry (ventral tegmental area, nucleus accumbens, prefrontal cortex). Activating these receptors appears to reduce dopamine responses to rewarding stimuli - food, alcohol, drugs - which may reduce the motivational pull of addictive substances. The "food noise quieting" that GLP-1 users commonly report may reflect the same mechanism that quiets alcohol and substance cravings.